https://scholars.lib.ntu.edu.tw/handle/123456789/568568
標題: | Chronic hepatitis B: Whom to treat and for how long? Propositions, challenges, and future directions | 作者: | Ahn S.H. Chan H.L.Y. PEI-JER CHEN Cheng J. Goenka M.K. Hou J. Lim S.G. Omata M. Piratvisuth T. Xie Q. Yim H.J. Yuen M.-F. |
關鍵字: | ALT; Chronic hepatitis B (CHB); HBV DNA; Hepatitis B virus (HBV); Interferon alfa; Nucleoside/nucleotide analog | 公開日期: | 2010 | 出版社: | Springer New York LLC | 卷: | 4 | 期: | 1 | 起(迄)頁: | 386-395 | 來源出版物: | Hepatology International | 摘要: | Recent guidelines of the American Association for the Study of Liver Diseases, the European Association for the Study of the Liver, and the Asian Pacific Association for the Study of the Liver 2008 update of the "Asian-Pacific consensus statement on the management of chronic hepatitis B" offer comprehensive recommendations for the general management of chronic hepatitis B (CHB). These recommendations highlight preferred approaches to the prevention, diagnosis, and treatment of CHB. Nonetheless, the results of recent studies have led to an improved understanding of the disease and a belief that current recommendations on specific therapeutic considerations, including CHB treatment initiation and cessation criteria, particularly in patient populations with special circumstances, can be improved. Twelve experts from the Asia-Pacific region formed the Asia-Pacific Panel Recommendations for the Optimal Management of Chronic Hepatitis B (APPROACH) Working Group to review, challenge, and assess relevant new data and inform future updates of CHB treatment guidelines. The significance of and controversy about reported findings were discussed and debated in an expert meeting of the Working Group in Beijing, China, in November 2008. This review paper attempts to identify areas requiring improved CHB management and provide suggestions for future guideline updates, with special emphasis on treatment initiation and duration. ? 2010 Asian Pacific Association for the Study of the Liver. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84984538817&doi=10.1007%2fs12072-010-9163-9&partnerID=40&md5=174abb69c5e7a2acdd72a241d49c0fd5 https://scholars.lib.ntu.edu.tw/handle/123456789/568568 |
ISSN: | 1936-0533 | DOI: | 10.1007/s12072-010-9163-9 | SDG/關鍵字: | adefovir; alanine aminotransferase; aspartate aminotransferase; clevudine; entecavir; hepatitis B surface antigen; hepatitis B(e) antigen; lamivudine; telbivudine; tenofovir; virus DNA; alanine aminotransferase blood level; aspartate aminotransferase blood level; chronic hepatitis; clinical trial; decompensated liver cirrhosis; disease course; elastography; hepatitis B; Hepatitis B virus; human; liver histology; myopathy; nephrotoxicity; neuropathy; nonhuman; patient assessment; practice guideline; priority journal; retreatment; review; seroconversion; treatment duration; treatment indication; treatment planning; unspecified side effect |
顯示於: | 臨床醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。